-

Viz.ai Strengthens Information Security with ISO-27001:2022 Certification

Certification validates Viz.ai One platform as trusted and secure for health systems

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the successful completion of the International Organization for Standardization (ISO) ISO-27001:2022 certification as well as additional ISO certificates including 22301:2019, 27017:2015, 27018:2019, 27032:2012, 27701:2019, and 27799:2016. Achieving this rigorous auditing standard further validates Viz.ai’s systematic and comprehensive approach to information security management practices and business continuity management systems.

“We’re proud to have achieved seven ISO certificates for the Viz.ai One platform without any major findings,” said Tom Vaknin, Chief Information Security Officer at Viz.ai. “Information security is critical for our customers and our organization. This milestone demonstrates our ongoing commitment to uphold the confidentiality, integrity, and availability of information assets as well as continued enhancement of our information security processes.”

ISO certificates are awarded to organizations that meet stringent criteria for establishing, implementing, maintaining, and continually improving information security management practices. Viz.ai received seven certificates for business continuity management, information security management system, process information in the cloud, processing Personally Identifiable Information (PII) in the cloud, cybersecurity, information security in health, and privacy information management system.

ISO is an independent, non-governmental international organization that develops and publishes international standards to ensure the quality, safety, efficiency, and interoperability of products, services, and systems. The certificates confirm that Viz.ai has effective information security management systems in place.

These ISO certifications follow Viz.ai’s successful completion of its SOC 2 Type 2 + HIPAA audit, which was announced in February of 2024. To learn more about Viz.ai’s robust security measures and compliance certifications, please visit the Viz.ai Trust Center.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Viz.ai


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...

Viz.ai Appoints Dr. Timothy N. Showalter as First Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Tim Showalter, MD, MPH, MBA, as its first Chief Medical Officer (CMO). Dr. Showalter, an accomplished academic radiation oncologist, will lead Viz.ai’s clinical strategy and advance the company’s mission to use artificial intelligence to improve access to life-saving care. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai. Dr. Sho...

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...
Back to Newsroom